title: Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer.
abstract: The effects of fullerenol C60(OH)24 (Frl) at doses of 25, 50, and 100mg/kg/week (for a time-span of 3 weeks) on heart and liver tissue after doxorubicin (Dox)-induced toxicity in rats with colorectal cancer were investigated. In the present study, we used an in vivo Wistar male rat model to explore whether Frl could protect against Dox-induced (1.5mg/kg/week for 3 weeks) chronic cardio- and hepato- toxicity and compared the effect with a well-known antioxidant, vitamin C (100mg/kg/week for 3 weeks). According to macroscopic, microscopic, hematological, biochemical, physiological, pharmacological, and pharmacokinetic results, we confirmed that, at all examined doses, Frl exhibits a protective influence on the heart and liver tissue against chronic toxicity induced by Dox.
authors.affiliation: Faculty of Pharmacy, Institute of Pharmaceutical Biology, University of Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia. injacrade@gmail.com
authors.forename: Rade
authors.initials: R
authors.lastname: Injac
authors.forename: Martina
authors.initials: M
authors.lastname: Perse
authors.forename: Manica
authors.initials: M
authors.lastname: Cerne
authors.forename: Nejka
authors.initials: N
authors.lastname: Potocnik
authors.forename: Natasa
authors.initials: N
authors.lastname: Radic
authors.forename: Biljana
authors.initials: B
authors.lastname: Govedarica
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Djordjevic
authors.forename: Anton
authors.initials: A
authors.lastname: Cerar
authors.forename: Borut
authors.initials: B
authors.lastname: Strukelj
mesh_terms: D034841:Abdominal Cavity / Q000473:pathology; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D054715:Cardiotoxins / Q000633:toxicity; D015179:Colorectal Neoplasms / Q000097:blood / Q000201:enzymology / Q000473:pathology*; D004317:Doxorubicin / Q000633:toxicity*; D004562:Electrocardiography; D004798:Enzymes / Q000097:blood; D037741:Fullerenes / Q000493:pharmacokinetics / Q000494:pharmacology*; D019803:Glutathione Disulfide / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000473:pathology; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D020011:Protective Agents / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D054715:Cardiotoxins; D004798:Enzymes; D037741:Fullerenes; D020011:Protective Agents; C108127:fullerenol; D008315:Malondialdehyde; D004317:Doxorubicin; D019803:Glutathione Disulfide